In EC, upon MPA treatment, TRPS1 could act as a transcription corepressor and interact with HDAC2 to form a PR/TRPS1/HDAC2 complex to deacetylate RANKL, downregulating the expression of RANKL and thereby exerting an anti-tumor effect. The gene discussed is TRPS1; the disease is neoplasm.